Incyte targets $3–4B by 2030 and $8–10B peak sales
Incyte management outlined a dual strategy of core business growth plus pipeline execution, targeting $3–4 billion by 2030 and $8–10 billion peak sales post-2029. Oncology, hematology and immunology assets are progressing.
Management said it is pursuing core business growth and pipeline execution, with a target of $3—4 billion by 2030 and $8—10 billion peak sales after 2029. The company said key assets in oncology, hematology and immunology are advancing, with major data readouts and launches expected through 2029.